291 related articles for article (PubMed ID: 36482400)
1. Development and validation of a new nomogram to screen for MAFLD.
Zou H; Zhao F; Lv X; Ma X; Xie Y
Lipids Health Dis; 2022 Dec; 21(1):133. PubMed ID: 36482400
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the diagnostic performance of twelve noninvasive scores of metabolic dysfunction-associated fatty liver disease.
Zou H; Ma X; Zhang F; Xie Y
Lipids Health Dis; 2023 Sep; 22(1):145. PubMed ID: 37674196
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a nomogram for predicting metabolic-associated fatty liver disease in the Chinese physical examination population.
Zhou B; Gong N; Huang X; Zhu J; Qin C; He Q
Lipids Health Dis; 2023 Jun; 22(1):85. PubMed ID: 37386566
[TBL] [Abstract][Full Text] [Related]
4. Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults.
Peng H; Pan L; Ran S; Wang M; Huang S; Zhao M; Cao Z; Yao Z; Xu L; Yang Q; Lv W
Front Endocrinol (Lausanne); 2023; 14():1083032. PubMed ID: 36742412
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a nomogram model for predicting the risk of MAFLD in the young population.
Yuan Y; Xu M; Zhang X; Tang X; Zhang Y; Yang X; Xia G
Sci Rep; 2024 Apr; 14(1):9376. PubMed ID: 38654043
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study.
Zhang F; Han Y; Mao Y; Zheng G; Liu L; Li W
Ann Med; 2024 Dec; 56(1):2337739. PubMed ID: 38574396
[TBL] [Abstract][Full Text] [Related]
7. Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters.
Xue Y; Xu J; Li M; Gao Y
Front Endocrinol (Lausanne); 2022; 13():951689. PubMed ID: 36120429
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the prognostic value of a comprehensive set of predictors in identifying risk of metabolic-associated fatty liver disease among employed adults.
Yang Z; Yu B; Wang Z; Li Z; Yang B; Zeng H; Yang S
BMC Public Health; 2023 Mar; 23(1):584. PubMed ID: 36991357
[TBL] [Abstract][Full Text] [Related]
9. The association of triglyceride-glucose-waist circumference with metabolic associated fatty liver disease and the severity of liver steatosis and fibrosis in American adults: a population-based study.
Wu Z; Huang K; Bao S; Zhang X; Li J; Kong W; Shi Y; Xie Y
Scand J Gastroenterol; 2024 May; 59(5):561-569. PubMed ID: 38235548
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the diagnostic value between triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio in metabolic-associated fatty liver disease patients: a retrospective cross-sectional study.
Liu Z; He H; Dai Y; Yang L; Liao S; An Z; Li S
Lipids Health Dis; 2022 Jun; 21(1):55. PubMed ID: 35752830
[TBL] [Abstract][Full Text] [Related]
11. [Establishment and Analysis of Risk Prediction Model for Metabolic Dysfunction-Associated Fatty Liver Disease in Physical Examination Population].
Xia B; He H; Qin K; Li SQ; An ZM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):591-595. PubMed ID: 37248589
[TBL] [Abstract][Full Text] [Related]
12. Prediction and Validation of Metabolic Dysfunction-Associated Fatty Liver Disease Using Insulin Resistance-Related Indices in the Japanese Population.
Moriyama K; Inoue N; Imai J; Masuda Y; Yamada C; Kishimoto N; Takashimizu S; Kubo A; Nishizaki Y
Metab Syndr Relat Disord; 2023 Nov; 21(9):489-496. PubMed ID: 37878804
[No Abstract] [Full Text] [Related]
13. Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease.
Cen C; Wang W; Yu S; Tang X; Liu J; Liu Y; Zhou L; Yu J; Zheng S
Hepatol Int; 2020 Sep; 14(5):808-816. PubMed ID: 32572817
[TBL] [Abstract][Full Text] [Related]
14. Modified triglyceride-glucose index indices are reliable markers for predicting risk of metabolic dysfunction-associated fatty liver disease: a cross-sectional study.
Kim AH; Son DH; Lee YJ
Front Endocrinol (Lausanne); 2023; 14():1308265. PubMed ID: 38317718
[TBL] [Abstract][Full Text] [Related]
15. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults.
Li H; Zhang Y; Luo H; Lin R
Front Endocrinol (Lausanne); 2022; 13():977625. PubMed ID: 36407325
[TBL] [Abstract][Full Text] [Related]
16. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease.
Duan SJ; Ren ZY; Zheng T; Peng HY; Niu ZH; Xia H; Chen JL; Zhou YC; Wang RR; Yao SK
World J Gastroenterol; 2022 Sep; 28(36):5364-5379. PubMed ID: 36185625
[TBL] [Abstract][Full Text] [Related]
17. Association between triglyceride glucose-related markers and the risk of metabolic-associated fatty liver disease: a cross-sectional study in healthy Chinese participants.
Chang M; Shao Z; Shen G
BMJ Open; 2023 May; 13(5):e070189. PubMed ID: 37130686
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Nomogram for Prediction of the Risk of MAFLD in an Overweight and Obese Population.
Song D; Ge Q; Chen M; Bai S; Lai X; Huang G; Liu M; Lin M; Xu J; Dong F
J Clin Transl Hepatol; 2022 Dec; 10(6):1027-1033. PubMed ID: 36381091
[TBL] [Abstract][Full Text] [Related]
19. Using new indices to predict metabolism dysfunction-associated fatty liver disease (MAFLD): analysis of the national health and nutrition examination survey database.
Li XM; Liu SL; He YJ; Shu JC
BMC Gastroenterol; 2024 Mar; 24(1):109. PubMed ID: 38491451
[TBL] [Abstract][Full Text] [Related]
20. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population.
Cai J; Lin C; Lai S; Liu Y; Liang M; Qin Y; Liang X; Tan A; Gao Y; Lu Z; Wu C; Huang S; Yang X; Zhang H; Kuang J; Mo Z
Lipids Health Dis; 2021 Oct; 20(1):145. PubMed ID: 34706716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
